E-Book, Englisch, Band 165, 469 Seiten, eBook
Kiss / Gottschalk / Pohlscheidt New Bioprocess Strategies
1. Auflage 2018
ISBN: 978-3-319-97110-0
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark
E-Book, Englisch, Band 165, 469 Seiten, eBook
Reihe: Advances in Biochemical Engineering/Biotechnology
ISBN: 978-3-319-97110-0
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
- Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie
- Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
Weitere Infos & Material
Market and Capacity evolvement of the Biopharmaceutical Industry.- New Mammalian Expression Systems.- Innovation in seed train cultivation and production culture.- Manufacturing of Proteins and Antibodies / Risk mitigation for the contamination by adventitious agents.- Harvest operations.- Downstream Processing Technologies / Capturing and Final Purifaction.- Fully disposable manufacturing concepts for clinical and commercial manufacturing and Ballroom Concepts.- Augmented Reality – PAT and Artificial Intelligence for innovative process monitoring and controls.- Trends and innovations in formulations, fill and finish technologies and drug delivery.- Process Integration towards continuous manufacturing.- Future direction of Manufacturing of novel molecular format - a research perspective (bispecific antibodies, ADC, Ab fragments, fusion proteins, etc.- Cell therapy manufacturing for modern therapeutics.- Gene therapy.- Modern technologies and strategies for vaccine manufacturing.- Product and Technology Lifecycle Management in the Pharmaceutical Industry.- Integrated High Throughput Development.- A different perspective – How much innovation is really needed for production of mAb by mammalian cell technology?